SGLT2 Inhibition in Heart Failure: New Updates
Published: 08 February 2023
29m 31sPart 1 Do the Kidneys Hold Clues to the HF Benefits Of SGLT2 Inhibitors? John JV McMurray
10m 53sPart 2 SGLT2 Inhibition in the Elderly and Frail Patients Pardeep Jhund
9m 34sPart 3 Gender Differences in Outcomes With SGLT2 Inhibitors Xiaowen “Wendy” Wang
10m 55sPart 4 Efficacy and Safety of SGLT2 Inhibitors in Black Patients Subodh Verma
15m 19sPart 5 Panel Discussion Harriette Van Spall, Nandini Gupta, Subodh Verma, John JV McMurray, Xiaowen “Wendy” Wang, Pardeep Jhund
10m 28sPart 6 SGLT2 Inhibition in Patients With Improved EF Orly Vardeny
13m 27sPart 7 SGLT2 Inhibition With MRAs and ARNis Muthiah Vaduganathan
11m 47sPart 8 Does NT-proBNP Affect the Efficacy of SGLT2 Inhibitors? Eileen O’Meara
20m 13sPart 9 Does EF Still Matter in HF Management? Scott Solomon
This on-demand version of the live broadcast provides the latest updates on SGLT2 Inhibition in heart failure.
Dr Harriette Van Spall (McMaster University, Hamilton, CA) and Dr Nandini Gupta (Mackenzie Health, Richmond Hill, CA) chair and co-chair the programme, and are joined by an outstanding international faculty for a series of insightful presentations and discussions.
Note, the live version of this session was CME accredited; this on-demand version is not.
- To explore the mechanisms of cardiorenal protection with SGLT2 inhibition
- To examine how the safety-efficacy relationship of SGLT2 inhibitors vary with age, frailty, gender and race
- To break down how SGLT2 inhibitors can be safely and optimally combined with other heart failure pharmacotherapies
- To recognise the prognostic value of NT-proBNP in SGLT2 inhibition
- To assess the merit of ejection fraction in heart failure care
- Primary Care Physicians
- Diabetes Educators
More from this programme
Do the Kidneys Hold Clues to the HF Benefits Of SGLT2 Inhibitors?
SGLT2 Inhibition in the Elderly and Frail Patients
Gender Differences in Outcomes With SGLT2 Inhibitors
Efficacy and Safety of SGLT2 Inhibitors in Black Patients
SGLT2 Inhibition in Patients With Improved EF
SGLT2 Inhibition With MRAs and ARNis
Does NT-proBNP Affect the Efficacy of SGLT2 Inhibitors?
Does EF Still Matter in HF Management?
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…
Director, Noninvasive Cardiology / Professor
Prof Scott D Solomon is the Edward D Frohlich Distinguished Chair at Harvard Medical School, Director of Noninvasive Cardiology and Senior Physician at Brigham and Women’s Hospital. His research group has played a leading role in clinical trials in heart failure, hypertension and myocardial infarction.
He received his AB from Williams College and his MD from Harvard Medical School.
Dr Vaduganathan is a Cardiologist and clinical trialist at Brigham and Women’s Hospital and Harvard Medical School. He is co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital. He is a co-chair of a Heart Failure Collaboratory committee focused on improving future clinical trials in heart failure, and serves on the planning committee of the Global CardioVascular Clinical Trialists Forum. He is a Section Editor of the Fellows-in-Training / Early Career section of JACC, Associate Editor of JACC Heart Failure, and serves on the editorial board of the European Journal of Heart Failure. His research focuses on drug development, clinical trials, and implementation of cardio-renal-metabolic therapies, and he has authored or co-authored more than 500 peer-reviewed publications. He participates on study leadership and on committees of ongoing advanced-phase trials in cardiometabolic medicine and heart failure.…
Associate Professor of Medicine
Dr Orly Vardeny is Associate Professor of Medicine at the University of Minnesota in Minneapolis. Her research interests include maximising the benefit of pharmacologic therapy in patients with heart failure and optimising vaccination strategies in patients with cardiac disorders. She has led several multi-center, randomized clinical trials evaluating influenza vaccines in patients with high-risk cardiovascular disease.
In addition, Dr Vardeny serves as the US national lead investigator and a steering committee member for numerous clinical trials investigating novel therapies in patients with heart failure. Her clinical practice is in the outpatient management of patients with chronic heart failure. She is an Associate Editor for Circulation: Heart Failure and was a writing group member for the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America Guidelines for the Management of Heart Failure.
Professor of Medicine
Dr Eileen O’Meara is Professor at the Department of Medicine at the University of Montreal and practices cardiology at the Montreal Heart Institute.
Dr O’Meara pursued a Fellowship in Heart Failure at the Western Infirmary & Glasgow Royal Infirmary in the UK, and another in Stress Echocardiography and Tissue Doppler at Hôpital Européen Georges Pompidou in Paris.
Her research focuses on remodeling and fibrosis biomarkers in HF, including cardiac imaging biomarkers; as well as on comorbid conditions that contribute to HF, more specifically diabetes, CKD, and anemia. Dr O’Meara has long been involved in clinical research on HF with preserved ejection fraction (HFpEF) and was the Canadian lead investigator for the TOPCAT and PARAGON-HF trials and co-national lead investigator for the DELIVER trial.